

PAR-22-114

**Administrative Supplements to
Support Cancer Disparity Collaborative Research
(Clinical Trial Optional)**

Pre-application Webinar

*Maria Jamela R. Revilleza, PhD, MSc
Sarah M. Szurek, PhD*

Center for Cancer Health Equity (CCHE)

July 30, 2024


The Collaborative Team at CCHE



**Maria Jamela R.
Revilleza, PhD, MSc**



**Sarah M. Szurek,
PhD**



**LeeAnn Bailey,
MBBS, PhD, MS**



**Ms. Molly
Boyajian**


Important Housekeeping Notes

- To preserve bandwidth, participants are requested to turn video off and stay muted for entire presentations
- Please type your questions/comments into the chat box throughout the presentation, to be addressed during the Q&A or via e-mail.
- Slides and the recorded webinar will be shared with the participants in a few days

Purpose and Outline

- To provide an introduction and overview of PAR-22-114 to prospective applicants
- Outline
 - Background
 - Definitions
 - Goals of FOA
 - Program Description and Requirements
 - Examples of Research Areas of Interest
 - Application Review Information
 - Award Information
 - Scientific/Research Contacts
- Q & A

Collaborative is an NCI-wide Program



- **Center for Cancer Health Equity (CCHE)**
Maria Jamela Revilleza, PhD, MS; mrevilleza@nih.gov
Sarah Szurek, PhD; sarah.szurek@nih.gov
- **Division of Cancer Biology (DCB)**
Natalia Mercer, PhD; natalia.mercer@nih.gov
- **Division of Cancer Control and Population Sciences (DCCPS)**
Amy Kennedy, PhD, MPH; amy.kennedy@nih.gov
- **Division of Cancer Prevention (DCP)**
Vikrant Sahasrabuddhe, MBBS, MPH, DrPH;
vikrant.sahasrabuddhe@nih.gov
- **Division of Cancer Treatment and Diagnosis (DCTD)**
Minkyung (Min) H. Song, PhD; songm@mail.nih.gov
- **Center for Global Health**
James R. Alaro, PhD; james.alaro@nih.gov

Background



- Significant advancements in cancer research have led to improved diagnosis, prognosis, and outcomes for cancer patients
- Despite this progress, cancer disparities remain among specific populations* for numerous types of cancers
 - * *Characterized by race, ethnicity, age, disability, gender identity, sexual orientation, geographic location, income, education, or other practices historically linked to discrimination or exclusion*
- Cancer Health Disparities (CHD) research is a priority area for NCI

Defining Cancer Disparities Research (CHD) and Comparative Design

- CHD addresses the **disproportionate cancer burden among racial/ethnic (R/E) minority and/or underserved populations** and seeks to understand and/or reduce differences in cancer outcomes
- Spans across the cancer continuum (prevention, early detection, diagnosis, treatment, and survivorship) and includes **comparative** biological, behavioral, environmental, social, clinical, or translational investigations among one or more R/E minority or underserved group

Examples of comparative research design:

- Scientific investigations in one R/E minority and/or underserved group compared to another population group
- Investigating a disease etiology in two different R/E minority and/or underserved groups
- Comparing health care barriers in one R/E minority and/or underserved group in different settings and/or environments

CHD are Differences in Cancer Measures



- Incidence (new cases)
- Prevalence (all existing cases)
- Mortality (deaths)
- Survival (how long people survive after diagnosis)
- Morbidity (cancer-related health complications)
- Survivorship (including quality of life after cancer treatment)
- Financial burden of cancer or related health conditions
- Screening rates
- Stage at diagnosis

The Collaborative Promotes Diversity in Cancer Research

NCI particularly encourages applications from individuals from groups identified in NIH's Notice of Interest in Diversity ([NOT-OD-20-031](#)) as underrepresented in the biomedical, clinical, behavioral, and social sciences.

Race/Ethnicity

- Blacks or African Americans
- Hispanics or Latinos
- American Indians or Alaskan Natives
- Native Hawaiians and other Pacific Islanders

Disability

- Physical or mental impairment that substantially limits one or more major life activities

Disadvantaged Background

- Homeless
- Foster care system
- First generation w/ Bachelor's degree
- Federal Pell Grants
- Special Supplemental Nutrition Program
- Rural or low income/access areas

PAR-22-114: Collaborative Program's Purpose

To increase the scope and depth of cancer health disparities (CHD) research



One of the only mechanisms to generate pilot data for R01 applications



Opportunity for eligible NCI-funded investigators to expand their research and include a CHD topic in Specific Aims



Encourages collaboration between the NCI PI and a CHD expert



Supports up to two years of funding



Up to 10 awards may be made for FY 2024

Collaborative Administrative Supplement at a Glance

- **PAR-22-114:** Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
- **Eligible NCI-funded grants:** *P01, P20, P50, U19, U54, U56, UM2, R01, R37, U01, UG1, UM1*
- **Budget:** Direct Cost of \$150k/year, Total Cost of \$255/year for two years
- **Application Due Dates:**
 - *September 06, 2024; January 23, 2025*
- **Start Date:** August 2025
- **Requirement:** Two years remaining on the parent grant at the time of submission

PAR-22-114 Eligibility Requirements



- Parent grant must NOT have proposed ***cancer health disparities research questions*** as part of the original scientific aims
- Proposal is required to be ***within the scope of the parent award*** and should expand the original aims to include a CHD component
- **Comparative Research Design** is required
- **Collaborative Research Teams and Expertise**
 - ***Applicant:*** An NCI awardee with an active grant (PI) with *no prior CHD experience*, interested in expanding the parent grant to include a CHD research question
 - ***Collaborator:*** A CHD or minority health researcher who will *collaborate* with the Applicant to address a CHD research question

PA-22-114 Additional Program Requirements

- Only researchers with the following active NCI-funded grants are eligible to apply (see [NOT-CA-20-006](#)):

P01, P20, P50, U19, U54, U56, UM2, R01, R37, U01, UG1, UM1

- *The parent grant must have at least 2 full years of active funding (excluding no-cost extension periods) remaining at the time of submission*
- Supplement awards cannot be used to support Principal Investigator salaries; however, they can support collaborator salaries
- A parent award is eligible to receive **only one administrative supplement of this type** under this NOFO (Other supplement mechanisms are allowable, e.g., diversity supplements)

The Collaborative is (Clinical Trial Optional)

- Administrative supplement applications may *NOT* propose changes to the overall human subjects or clinical trial (CT) designation of the award.
- The administrative supplement *CANNOT* contain a clinical trial unless the parent grant has one. However, the supplement may not have CT even if the parent award has one.


Application Review Information

Applications will undergo programmatic review by NIH staff who will evaluate for overall merit and the following general criteria:

- Fit within the scope of the parent grant
- Research question(s) that address R/E minority and/or underserved populations
- Comparative research design
- Qualifications of key personnel
 - *Is a track record of the collaborator in cancer health disparities or minority health research included?*
 - *Ensure that the contact PI does not have a record of CHD expertise (first/last/corresponding author on pubs, award received that address CHD topics, speaking engagements, etc.)*
- Sound experimental design and feasibility
- Likelihood for the project to exert a sustained, powerful influence on CHD research

Specific Areas of Research Interest

- Basic Cancer Biology
- Cancer Prevention
- Population Sciences
- Translational and Clinical Studies
- Global Health



Review of Applications

Administrative
Review

Applications Received



Eligibility screen by
program staff



Parent PD confirmation



Review by primary and
secondary reviewers



Applications ranked
based on combined
scores



Final discussion with WG
to identify top 10

Scientific
Review

Summary

- This mechanism supports:
 - Innovative, multidisciplinary, and state-of-the-art collaborations focused on CHD of R/E minority populations that include a wide arrange of strategies from cellular, mouse, and access to and use of large data sets and bioinformatics/machine learning tools.
 - The development of non-invasive diagnostic tools that are practical, cost-effective, and accessible at local sites and settings.
- All applicants/teams should express leveraging the supplement to generate data from the eligible research activity mechanisms in support of future disparities-focused NCI Awards, providing new trajectories in CHD research strategies.
- We are excited about the continued expansion into new cancers and additional population foci.
- Addition of cancer health disparities components to meritorious science that NCI has already invested in.

Thank You and Acknowledgements

- **NCI Workgroup**

- Natalia Mercer, PhD
- Amy Kennedy, PhD, MPH
- Vikrant Sahasrabuddhe, MBBS, DrPH
- Minkyung Song, PhD
- James Alaro, PhD

- **Collaborative Management:**

- LeeAnn Bailey, MD, PhD
- Molly Boyajian, Program Analyst

- **Dr. Sanya A. Springfield**

Thank you!

Send inquiries to:

collaborative@mail.nih.gov



A large, stylized graphic featuring the text "Q&A" in white, bold, sans-serif font. The text is centered and surrounded by numerous blue squares of various sizes and shades of blue. Some of these squares contain white question marks, creating a visual theme of inquiry and questions. The background is white, and the overall design is clean and modern.



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol